TipRanks
Go Ultimate55% OFF

Compare Neuroscientific Biopharmaceuticals Ltd. (MSX) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
AU:MSXNeuroscientific Biopharmaceuticals Ltd.AUD 0.05AUD 19.49M-3.88-50.00%―Unlock the AU:MSX analyst price target with TipRanks PremiumAU:MSXUnlock the AU:MSX top-analyst price target with TipRanks Premium
AU:ACWActinogen Medical AUD 0.04AUD 162.72M-8.7523.53%Moderate BuyUnlock the AU:ACW analyst price target with TipRanks PremiumAU:MSX vs AU:ACWUnlock the AU:ACW top-analyst price target with TipRanks Premium
AU:NEUNeuren Pharmaceuticals LimitedAUD 20.75AUD 2.58B128.62-7.20%Strong BuyUnlock the AU:NEU analyst price target with TipRanks PremiumAU:MSX vs AU:NEUUnlock the AU:NEU top-analyst price target with TipRanks Premium
AU:ATHAlterity TherapeuticsAUD 0.26AUD 60.72M-2.40-51.82%Moderate BuyUnlock the AU:ATH analyst price target with TipRanks PremiumAU:MSX vs AU:ATHUnlock the AU:ATH top-analyst price target with TipRanks Premium
AU:ZLDZelira TherapeuticsAUD 0.50AUD 5.95M-1.5651.52%―Unlock the AU:ZLD analyst price target with TipRanks PremiumAU:MSX vs AU:ZLDUnlock the AU:ZLD top-analyst price target with TipRanks Premium
AU:PYCPYC Therapeutics LimitedAUD 1.90AUD 1.85B-31.8162.49%Strong BuyUnlock the AU:PYC analyst price target with TipRanks PremiumAU:MSX vs AU:PYCUnlock the AU:PYC top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
AU:MSXNeuroscientific Biopharmaceuticals Ltd.0.05-0.09-65.52%
AU:ACWActinogen Medical 0.040.0116.67%
AU:NEUNeuren Pharmaceuticals Limited20.36-0.44-2.10%
AU:ATHAlterity Therapeutics0.27-0.23-47.00%
AU:ZLDZelira Therapeutics0.500.1542.86%
AU:PYCPYC Therapeutics Limited1.880.6957.85%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts